Ferring Pharmaceuticals, USA today announced the U.S. commercial availability of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. FDA for the treatment of hormone sensitive advanced prostate cancer. Degarelix is available for order through traditional and specialty pharmacy distributors.
The details can be read here.
No comments:
Post a Comment